Wuhan Humanwell Innovative

Company snapshot

Wuhan Humanwell Innovative is a pharma organization headquartered in CN. Primary therapeutic focus areas include Advanced Solid Tumors. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Wuhan Humanwell Innovative. Not investment advice.

• What is Wuhan Humanwell Innovative?

  Wuhan Humanwell Innovative is a pharma organization headquartered in CN. Primary therapeutic focus areas include Advanced Solid Tumors. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, a

• Is Wuhan Humanwell Innovative publicly traded?

  Wuhan Humanwell Innovative appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Wuhan Humanwell Innovative develop or market?

  We link 2 drug profile(s) where Wuhan Humanwell Innovative is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/wuhan-humanwell-innovative-drug-research-and-development-center-limited-company#company-drugs.

• What are the latest developments for Wuhan Humanwell Innovative?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Wuhan Humanwell Innovative focus on?

  Wuhan Humanwell Innovative focuses on Advanced Solid Tumors based on our analysis of their pipeline programs and drug development activities.